Istradefylline is currently approved for treating OFF episodes in PD based on clinical trials conducted in Japan and the U.S. However, as the first adenosine A2A receptor antagonist used in PD, its full therapeutic potential remains unclear and requires further investigation in real-world settings. This evidence concerns the gene ADORA2A and Parkinson disease.